Vistagen to present fasedienol and itruvone data at ASCP conference May 28-31

Vistagen Therapeutics, Inc.

Poster on fasedienol (Phase 3 for social anxiety disorder) from PALISADE-2 trial on May 29.
Poster on intranasal itruvone (Phase 2 for major depressive disorder) distribution in rats on May 29.
Posters will be available on Vistagen website on June 3, 2024.

item 8.01 item 9.01

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-018214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.